Biomedical beauty group UltraV (CEO Dr. Han Jin Kwon) is beginning to enter the Chinese market with its self-developed PDO (polydioxanone) filler 'UltraCol'.

'Ultracol' received approval from China's CFDA (currently NMPA), certified by Hainan Province, in December last year, is currently undergoing biological safety evaluation, and plans to submit for clinical trials within 3 months.

China is one of the medical aesthetics markets with the highest growth potential in the world, and China's filler market is expected to grow from approximately 950 billion won (4.9 billion yuan) in 2020 to approximately 3 trillion won (15.7 billion yuan) in 2025.

To tap into the Chinese market, Ultra V signed a business agreement (MOU) with Chinese distributor WUDELAWEI, distribution manager Sinopharm Group Medicine, and CRO manager Tigermed Consulting. By first targeting the Hainan region, a special medical and tourism zone in China, UltraV is accumulating clinical data and is progressing smoothly intending to obtain product approval in mainland China in the second half of 2025.

A company official said, ‘UltraCol’ is a product developed with Ultra V's proprietary technology and consists of microspheres made of PDO ingredients. After the injection, it decomposes in the body and does not require separate removal, without side effects such as nodules and granulomas. “There is almost no risk, and due to the nature of the ingredients, it naturally helps collagen production, helping to improve wrinkles and elasticity.”

Recognized for its excellence in the world's first PDO material filler manufacturing and mass production technology, it won the IR52 Jang Young-sil Award in 2020. It has a history of winning the Korea Patent Award, has KFDA certification from the Korean Ministry of Food and Drug Safety and CE certification from Europe, and has already been sold in Asia, Europe, South America, and Korea. This product has contributed to sales growth by introducing the product all over the world, including the Middle East market.

Ultra V official said, "The Chinese cosmetic medical field is recording high growth every year. As we are recognized for our excellent product quality and are continuing to grow not only in Korea but also in the global market, we will become a representative product in the newly entering Chinese market." “We will do our best to make it happen,” he said.

Ultra V plans to expand exports, starting with the Chinese market, and pursue listing on KOSDAQ starting in the second half of 2024. As ‘UltraCol’ led the rapid growth, operating profit and loss turned to surplus since last year, and sales also shifted to a growth trend.

The company also announced that it expects that ‘UltraCol’ will achieve good results in the Chinese market by leveraging its effective safety.

Ultra V is currently in the process of registering 'UltraCol' to receive approval from ANVISA, The Brazilian Health Surveillance Agency, and is expected to receive product approval in June of this year. Ultra V plans to start selling the product as soon as this process is completed.​